ABSTRACT

The introduction and dissemination of 2019 novel coronavirus (2019-nCoV) or the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is presenting the planet with new public health emergencies. The virus appeared in bats and was transferred to humankind in December 2019 through still unidentified intermediate wildlife in Wuhan, Hubei Province, China. . The disease is spread by combustion or interaction with infectious droplets, and the time of incubation varies between 2 to 14 days. The signs generally include fever, cough, sore throat, shortness of breath, tiredness, malaise and others. The condition is moderate in many other individuals; it can lead to influenza, acute respiratory distress syndrome (ARDS), and multi-organ failure in others (usually the elderly and others with comorbidities). A lot of people are symptomless. The fatality rate of accidents is measured at 2 to 3 per cent. Treatment plan is by specialized genetic examination, by showing the virus in respiratory secretions. Different experimental results involve regular / low counts of white cells with elevated C-reactive protein (CRP). Computerized tomographic chest scanning is ordinarily anomalous except in those without symptoms or minor illness. Treatment is largely supportive; antiviral agent function is yet to be identified. Risk reduction includes residential segregation of suspicious patients as well as those with minor diseases in hospitals to require touch and dropletmonitoring, and stringent infection management procedures. The virus is spreading the SARS-CoV and Middle East coronavirus respiratory syndrome (MERS-CoV) quicker than its two predecessors, but has lower fatality. Although unclear is the economic influence of this new outbreak. Keyword: COVID-19; Corono virus; WHO; Respiration problem
Publication date: 01/09/2020

https://ijbpas.com/pdf/2020/September/MS_IJBPAS_2020_5184.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2020/9.9.5184